Walk­ing the walk, Al­ny­lam ap­points for­mer FDA head Mar­garet Ham­burg to the board

Right on the heels of an in­dus­try-wide no­tice from BIO to speed up gen­der di­ver­si­ty in the C-suite and board­room, Al­ny­lam is adding to its ros­ter with the ap­point­ment of for­mer FDA com­mis­sion­er Mar­garet Ham­burg to the board.

The let­ter, prompt­ed by a slate of con­tro­ver­sies over the lack of gen­der di­ver­si­ty and in­clu­sion dur­ing high-lev­el con­fer­ences such as JPM and BIO, was signed off by Al­ny­lam CEO John Maraganore, this year’s chair­man, along with Halozyme chief He­len Tor­ley and BIO chief Jim Green­wood.

Slat­ed to be­come a di­rec­tor on Jan­u­ary 10, 2019, Ham­burg takes the seat of John Clarke, who’s re­tir­ing from the board af­ter 16 years of ser­vice — in­clud­ing 13 years as the chair.

Ham­burg is the fourth woman on the cur­rent board of Al­ny­lam, join­ing Mar­sha Fanuc­cia, Amy Schul­man and Colleen Re­i­tan. As chair­man of in­dus­try group BIO, Al­ny­lam CEO John Maraganore has made di­ver­si­ty and in­clu­sion a pri­or­i­ty, with a goal of putting more women on cor­po­rate boards.

John Maraganore

“We are hon­ored to wel­come Peg­gy to our Board at a land­mark mo­ment for Al­ny­lam, hav­ing just re­cent­ly an­nounced the reg­u­la­to­ry ap­proval of the first RNAi ther­a­peu­tic,” said Maraganore.

Ham­burg’s most no­table stint is her time as FDA com­mis­sion­er dur­ing the Oba­ma years — 2009 to 2015 — where she served the sec­ond longest tenure. Pri­or to her lead role at the agency, she has spent time un­der the Clin­ton ad­min­is­tra­tion as as­sis­tant sec­re­tary for plan­ning and eval­u­a­tion at HHS as well as a gig as New York City’s health com­mis­sion­er. She is cur­rent­ly serv­ing as for­eign sec­re­tary of the Na­tion­al Acad­e­my of Med­i­cine, pres­i­dent-elect of AAAS and holds seats on a pletho­ra of oth­er boards, as well as a role on the Bill and Melin­da Gates Foun­da­tion Ad­vi­so­ry Com­mit­tee.

“I’m very pleased to be join­ing the Board — Al­ny­lam has kept a sus­tained fo­cus on cut­ting-edge bio­med­ical re­search, pi­o­neer­ing and lead­ing the field of RNAi ther­a­peu­tics to cre­ate a new class of med­i­cines,” said Ham­burg. “I look for­ward to work­ing with Al­ny­lam on in­no­v­a­tive ap­proach­es to help ex­pe­dite de­vel­op­ment of in­ves­ti­ga­tion­al ther­a­pies that ad­dress un­met med­ical needs.”


With con­tri­bu­tion from Am­ber Tong

Im­age: May­nard Clark; CC BY-SA 4.0

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDA’s orphan status for remdesivir — reserved to encourage the development of rare disease therapies — Gilead CEO Daniel O’Day had some explaining to do about the company’s approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program — one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

John Reed, Sanofi’s global head of R&D (Image: Endpoints News)

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

Sanofi and Regeneron have hustled up a second pivotal trial for their IL-6 drug Kevzara as a potential therapy for severe cases of Covid-19. The partners swiftly assembled a study drawing patients from Italy, Spain, Germany, France, Canada and Russia, planning to sign up 300 patients in a Phase II to test a low and high dose of Kevzara against placebo, setting the stage for the Phase III followup.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man test­ing

The global nature of the Covid-19 pandemic is manifesting more profoundly every day. With Spain’s death toll now surpassing China’s and India on full lockdown, the number of confirmed cases around the world has exceeded 436,000 while recoveries edged close to 112,000.

While the outbreak derails R&D at another pharma giant, several drugmakers have some encouraging updates on both experimental and repurposed molecules. Philanthropic campaigns in anticipation of the economic fallout continue. An Australian biotech is taking extreme measures to hunker down. There’s also an alternative epidemiology model emerging out of the UK, stirring up more discussion regarding the true extent of the infections in the country.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.